Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Emergency Room Use of "Fast-Track" Ultrasound in Acute Stroke: An Observational Study.

Connolly F, Röhl JE, Guthke C, Wengert O, Valdueza JM, Schreiber SJ.

Ultrasound Med Biol. 2019 Feb 14. pii: S0301-5629(19)30005-5. doi: 10.1016/j.ultrasmedbio.2019.01.001. [Epub ahead of print]

PMID:
30773376
2.

Devastating humoral CIDP variant remitted by autologous stem cell transplantation.

Scheibe F, Alexander T, Prüss H, Wengert O, Harms L, Angstwurm K, Hiepe F, Arnold R, Meisel A.

Eur J Neurol. 2016 Mar;23(3):e12-4. doi: 10.1111/ene.12896. No abstract available.

PMID:
26918747
3.

Multiple sclerosis: the elevated antibody response to Epstein-Barr virus primarily targets, but is not confined to, the glycine-alanine repeat of Epstein-Barr nuclear antigen-1.

Ruprecht K, Wunderlich B, Gieß R, Meyer P, Loebel M, Lenz K, Hofmann J, Rosche B, Wengert O, Paul F, Reimer U, Scheibenbogen C.

J Neuroimmunol. 2014 Jul 15;272(1-2):56-61. doi: 10.1016/j.jneuroim.2014.04.005. Epub 2014 Apr 16.

PMID:
24798244
4.

Human African trypanosomiasis with 7-year incubation period: clinical, laboratory and neuroimaging findings.

Wengert O, Kopp M, Siebert E, Stenzel W, Hegasy G, Suttorp N, Stich A, Zoller T.

Parasitol Int. 2014 Jun;63(3):557-60. doi: 10.1016/j.parint.2014.02.003. Epub 2014 Mar 5.

PMID:
24613272
5.

Neurosarcoidosis: correlation of cerebrospinal fluid findings with diffuse leptomeningeal gadolinium enhancement on MRI and clinical disease activity.

Wengert O, Rothenfusser-Korber E, Vollrath B, Bohner G, Scheibe F, Otto C, Hofmann J, Angstwurm K, Ruprecht K.

J Neurol Sci. 2013 Dec 15;335(1-2):124-30. doi: 10.1016/j.jns.2013.09.008. Epub 2013 Sep 11.

PMID:
24071064
6.

Proresolution lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial.

Prüss H, Rosche B, Sullivan AB, Brommer B, Wengert O, Gronert K, Schwab JM.

PLoS One. 2013;8(2):e55859. doi: 10.1371/journal.pone.0055859. Epub 2013 Feb 8.

7.

Immune-mediated necrotizing myopathy is characterized by a specific Th1-M1 polarized immune profile.

Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, Koch A, Heppner FL, Stenzel W.

Am J Pathol. 2012 Dec;181(6):2161-71. doi: 10.1016/j.ajpath.2012.08.033. Epub 2012 Oct 8.

PMID:
23058368
8.

Cerebral amyloid angiopathy-related inflammation: a treatable cause of rapidly-progressive dementia.

Wengert O, Harms L, Siebert E.

J Neuropsychiatry Clin Neurosci. 2012 Winter;24(1):E1-2. doi: 10.1176/appi.neuropsych.11010018. No abstract available.

PMID:
22450625
9.

Diagnostic pitfalls: a case of neurosarcoidosis mimicking tuberculous meningitis.

Scheibe F, Flick H, Wengert O, Wittschieber D, Bohner G, Ruokonen P, Harms L, Ruprecht K, Angstwurm K.

J Neurol. 2012 Aug;259(8):1736-9. doi: 10.1007/s00415-012-6429-2. Epub 2012 Feb 4. No abstract available.

PMID:
22307383
10.

A case of neuro-Behçet's mimicking herpes encephalitis.

Wengert O, Ghaeni L, Siebert E, Dreier JP.

Clin Neurol Neurosurg. 2012 Jul;114(6):721-4. doi: 10.1016/j.clineuro.2011.12.005. Epub 2011 Dec 30. No abstract available.

PMID:
22209146
11.

Images in clinical medicine. Baló's concentric sclerosis.

Wengert O, Siebert E.

N Engl J Med. 2011 Aug 25;365(8):742. doi: 10.1056/NEJMicm1008401. No abstract available.

12.

Progressive external ophthalmoplegia as initial manifestation of sporadic late-onset nemaline myopathy.

Wengert O, Meisel A, Kress W, Dekomien G, Angstwurm K, Heppner FL, Goebel HH, Stenzel W.

J Neurol. 2011 May;258(5):915-7. doi: 10.1007/s00415-010-5819-6. Epub 2010 Nov 12. No abstract available.

PMID:
21072530
13.

Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis.

Weber A, Wandinger KP, Mueller W, Aktas O, Wengert O, Grundström E, Ehrlich S, Windemuth C, Kuhlmann T, Wienker T, Brück W, Zipp F.

J Neuroimmunol. 2004 Apr;149(1-2):195-201.

PMID:
15020080
14.

TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis.

Wandinger KP, Lünemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, Grundström E, Ehrlich S, Wernecke KD, Volk HD, Zipp F.

Lancet. 2003 Jun 14;361(9374):2036-43.

PMID:
12814715
15.

Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients.

Gniadek P, Aktas O, Wandinger KP, Bellmann-Strobl J, Wengert O, Weber A, von Wussow P, Obert HJ, Zipp F.

J Neuroimmunol. 2003 Apr;137(1-2):187-96.

PMID:
12667663

Supplemental Content

Loading ...
Support Center